December 1, 2014

homepage

December 13, 2017

X-Chem and Abilita Bio Announce a Joint Research Collaboration

(XChem), and Abilita Bio, Inc. (Abilita), both privately held biotechnology companies, announce today a joint research collaboration that will leverage the synergy between each company’s platform technology to enable the discovery of novel modulators of high-value G-protein coupled receptors (GPCR) and ion channel targets.

Continue Reading
November 28, 2017

X-Chem and Gilead Announce Drug Discovery Collaboration

WALTHAM, Mass. – November 28, 2017 – X-Chem, Inc. (X-Chem), a privately held biotechnology company applying its innovative drug discovery platform to the generation of novel small molecule therapeutics, announced today a drug discovery partnership with Gilead Sciences, Inc. (Gilead). Under the terms of the agreement, XChem will screen its proprietary DEXTM libraries, which contain […]

Continue Reading
October 31, 2017

Consortium of X-Chem, Harvard T.H. Chan School of Public Health and Other Leading Academic Institutions Wins Research Award from the Department of Defense

X-Chem, Inc., a privately held biotechnology company with a proprietary and innovative platform to generate small molecule therapeutics, today announced the award of a DOD CDMRP research grant entitled “Chemigenomic Drug Discovery for Tuberculosis.” The grant was awarded to a research consortium led by Eric Rubin, M.D., Ph.D., Irene Heinz professor of Immunology and Infectious […]

Continue Reading